| Ytd | -30.78% | |
| 1y | -36.33% |
| Open | 1.09 | Prev Close | 1.00 | Low | 1.02 | High | 1.09 | Mkt Cap | 63.63M |
| Vol | 87.61K | Avg Vol | 225.13K | EPS | -0.32 | P/E | -3.16 | Forward P/E | -13.63 |
| Beta | 0.46 | Short Ratio | 0.57 | Inst. Own | 1.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-08 | 50-d Avg | 1.27 | 200-d Avg | 1.48 | 1yr Est | 3.00 |
TLSA News
Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) outlined higher long-term revenue and earnings targets at its
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has rec
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, pl
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, pl
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or t
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a b
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will present at the Jefferies Global Healthcare Conf
UBS is sticking with a Buy rating on FedEx Corp (NYSE:FDX, XETRA:FDX) and a price target of $445, as
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evalu
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evalu
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Ph
3:40pm: Proactive news headlines Tiziana Life Sciences Ltd (NASDAQ:TLSA) completed patient enrollmen
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a b
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Ph
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on
MongoDB Inc (NASDAQ:MDB) saw Bank of America raise its price target on the database software company
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access P
Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access P
Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported PET imaging results from two patients in a Phase 2
